Robert E. George - 25 May 2023 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Reporting relationship: Director
Issuer ticker: MBRX
Reported as of: 25 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2023, 17:15:20 UTC
Prior SEC filing: 22 Jun 2022
Next SEC filing: 27 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Foster by Power of Attorney

Key filing fact

Robert E. George filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 26 May 2023.

Key facts

This page summarizes Robert E. George's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 May 2023, 17:15.

Change

Previous filing in this sequence was filed on 22 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBRX transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +15,000
Change %: +23%
Price
Shares after: 80,001
Date: 25 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.6200
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options set forth in this table vest on the earlier of one year from the date of the Company's 2023 annual meeting of stockholders or on the next annual meeting of stockholders, subject to the grantee's continued service on the Company's Board of Directors on such vesting date.

Footnote F2

The options were issued in connection with the reporting person's Board of Director service to the Company.